REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Find a specialty pharmacy.

List of specialty pharmacies.

REVLIMID is only available through a select network of specialty pharmacies due to a restricted distribution program called Lenalidomide REMS.1 These specialty pharmacies help to manage the handling and shipping of REVLIMID and may provide additional resources.


Reference: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp.